Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

LIDDS Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Mats Wiking

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

CEO

Mats Wiking (55 yo)

less than a year

Görev süresi

Mats Wiking serves as the CEO, Head of IR and CFO of LIDDS AB (publ) since September 01, 2024. Mats Wiking has long financial experience as Finance Director, Controller and Business Developer from both sma...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mats Wiking	CEO, CFO & Head of IR	less than a year	Veri yok	Veri yok
Monica Wallter	Senior Advisor	3.5yrs	SEK 1.87m	Veri yok
Kia Bengtsson	Head of Clinical Development	2yrs	Veri yok	Veri yok
Roger Belusa	Chief Medical Officer	1.6yrs	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: LIDDS 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Stefan Rehnmark	Independent Director	less than a year	Veri yok	4.86% SEK 729.6k
Torbjörn Browall	Director	less than a year	Veri yok	3.48% SEK 522.5k
Lars-Inge Sjoqvist	Director	less than a year	Veri yok	Veri yok
Daniel Lifveredson	Chairman	less than a year	SEK 66.00k	20.28% SEK 3.0m
Bengt Viterius	Deputy Board Member	less than a year	Veri yok	Veri yok

0.8yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LIDDS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

LIDDS Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

LIDDS AB (publ) Announces CFO Changes, Effective 1 September 2024

LIDDS AB (publ), Annual General Meeting, May 27, 2024

LIDDS AB (publ) Approves Board Elections

Lidds AB (Publ) Announces Resignation of Daniel Lifveredson from Board of Directors

LIDDS AB (publ) Announces CEO Changes

High number of new directors

Recent updates

LIDDS AB (publ) to Report Fiscal Year 2024 Results on Feb 20, 2025

LIDDS AB (publ) to Report Nine Months, 2024 Results on Nov 21, 2024

LIDDS AB (publ) to Report First Half, 2024 Results on Aug 28, 2024

LIDDS AB (publ) Announces CFO Changes, Effective 1 September 2024

New major risk - Shareholder dilution

LIDDS AB (publ), Annual General Meeting, May 27, 2024

LIDDS AB (publ) (OM:LIDDS) completed the acquisition of Noviga Research AB.

LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB.

LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB.

LIDDS AB (publ) Approves Board Elections

LIDDS AB (publ) to Report Fiscal Year 2023 Final Results on Apr 23, 2024

Lidds AB (Publ) Announces Resignation of Daniel Lifveredson from Board of Directors

LIDDS AB (publ) to Report Q1, 2024 Results on May 15, 2024

First half 2023 earnings released: kr0.29 loss per share (vs kr0.58 loss in 1H 2022)

LIDDS AB (publ) Announces CEO Changes

New major risk - Financial position

First quarter 2023 earnings released: kr0.29 loss per share (vs kr0.29 loss in 1Q 2022)

Full year 2022 earnings released: kr1.07 loss per share (vs kr1.16 loss in FY 2021)

LIDDS AB (publ) to Report Fiscal Year 2022 Results on Apr 25, 2023

Third quarter 2022 earnings released: kr0.23 loss per share (vs kr0.26 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.29 loss per share (vs kr0.32 loss in 2Q 2021)

LIDDS AB (publ) to Report Fiscal Year 2022 Results on Feb 24, 2023

High number of new directors

LIDDS AB (publ) Announces CEO Changes

LIDDS Patent Covering the NanoZolid® Production Process Granted in Israel

LIDDS AB (publ) Announces Board Changes

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

First quarter 2022 earnings: EPS and revenues miss analyst expectations

LIDDS AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

No independent directors

LIDDS AB (publ) announced that it expects to receive SEK 40.8 million in funding from Nice & Green SA

LIDDS AB Next Step with Nanozolid® Formulated Docetaxel

LIDDS AB Announces Positive Topline Results from the Phase I Dose-Escalating Study of NanoZolid-Formulated Docetaxel

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

Will LIDDS (STO:LIDDS) Spend Its Cash Wisely?

Here's Why We're Not Too Worried About LIDDS' (STO:LIDDS) Cash Burn Situation

Director recently bought kr159k worth of stock

LIDDS AB (publ) Enters R&D Agreement with Potential Exclusive, Global Product License Option

New 90-day low: kr13.50

LIDDS AB (publ) and Pharmidea Signs Manufacturing Agreement

LIDDS Files Patent Application for Method to Treat Brain Cancer with Intratumoral Depot Injections

LIDDS AB (publ) Provides Update on Chinese Conditional Market Approval (CMA) for Liproca® Depot

LIDDS AB (publ) Announces Management Changes, Effective April 19, 2021

We're Not Very Worried About LIDDS' (STO:LIDDS) Cash Burn Rate

New 90-day low: kr13.00

New 90-day low: kr13.10

LIDDS AB (publ) Announces Data on Liproca Depot from Open Label Extension Study

New 90-day high: kr16.15

LIDDS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 37.083996 million.

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş